The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Cooley (UK) LLP

Living Wage
Work 020 7583 4055
Fax 020 7785 9355

Stephen Rosen

Work +44 (0) 20 7583 4055
Cooley LLP

Work Department

Emerging Companies
Life Sciences
Mergers & Acquisitions
Venture Capital
Private Equity


Stephen Rosen is a partner in our London office. Stephen's experience is in acting for high growth companies, investors, entrepreneurs and management teams on corporate transactions with particular expertise on company sales and purchases, mergers and acquisitions and private equity and venture capital financings across a range of industry sectors. Stephen also regularly acts for spin outs, VC funded companies and well known investors in the life sciences sector.

Clients have said that Stephen is "incredibly smart and switched on" and "can be tough when required but is also calm and fair" and "he stands out for his tenacity and ability to deliver practical solutions when problems arise." Further comments include "Stephen was acting on the other side to us and we were so impressed we asked him to help us on our next deal."


Prior to joining Cooley in 2016, Stephen was at Olswang where he was previously Head of Corporate, London and Head of Private Equity and Venture Capital and a partner for 14 years.


  • Chester College of Law
    LSF, 1993
  • University of Leeds
    LLB, 1992

London: Corporate and commercial

M&A: lower mid-market deals, £50m-£250m

Within: M&A: lower mid-market deals, £50m-£250m

Cooley (UK) LLP 's department is especially strong in technology and life sciences. Its work tends to be in private M&A rather than public M&A, though the team has no shortage of listed clients; David Bresnick acted for Zenith Hygiene Group on its recommended final cash offer to sell to Bain Capital Private Equity through its investment in Diversey. 3Legs Resources is another listed client. In the retail space, department head  Justin Stock advised RZC Investments and Steuart Walton on the purchase of upmarket cycling brand Rapha, while on the technology side Stephen Rosen was instructed by senior management of ATCORE group on relation to the company’s acquisition by Inflexion Private Equity. Other clients include Apollo Global Management, Syncsort and YummyApps.

[back to top]

Venture capital

Within: Venture capital

Cooley (UK) LLP 's relatively new London office continues to gain market visibility and excels in deals which involve a transatlantic component. 'Excellent' US-qualified team head Ryan Naftulin represents companies and investors who are forming and financing disruptive high-growth companies, particularly in the technology and life sciences sectors. He recently advised SoftBank as the lead investor on London-based virtual reality company Improbable’s $502m Series B funding round. Although he is better known for his midmarket private equity prowess, Stephen Rosen also has experience in the venture capital market and in a deal which involved significant input out of the US, recently acted for Orchard Therapeutics on its $110m Series B financing. David Bresnick is also recommended. Other clients include Business Growth Fund, Draper Esprit and Sapphire Ventures.

[back to top]

London: TMT (technology, media and telecoms)

Pharmaceuticals and biotechnology

Within: Pharmaceuticals and biotechnology

The 'excellent' Cooley (UK) LLP handles IP and transactional matters in this sector. The 'outstanding' John Wilkinson jointly heads the practice and has 'an encyclopaedic knowledge of life sciences and legal detail'. He has expertise in the areas of IP, regulatory, competition and transactions, and recently advised Addex on its collaboration with Individior with the aim of developing a product to treat addiction. Fellow practice head Nicola Maguire is an expert in non-contentious IP issues and assisted PhoreMost with licensing technology from the University of Turin. Patent attorney Colm Murphy defended Illumina against challenges to its patents after it acquired Solexa. Corporate transactions specialist Stephen Rosen advised Orchard Therapeutics on its $110m Series B financing from Baillie Gifford and ORI Capital. Corporate specialist Ed  Lukins is also recommended.

[back to top]

Back to index

Legal Developments in London

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to